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Summary 
We previously reported that ceramide,  the immediate product of sphingomyelin hydrolysis, in- 
creases in response to interleukin (IL)-I~ and plays a role in modulating IL-l~-mediated prosta- 
glandin E2 production and cyclooxygenase gene expression in human fibroblasts (Ballou, L. K., 
C. P. Chao, M. A. Holness, S. C. Barker, and R. Raghow. 1992..1. Biol. Chem. 267:20044-20050). 
Here we describe the effects of ceramide in another II.,1B-mediated process in these cells, the 
induction of Ib6 production. We found that submicromolar concentrations of C2-ceramide in- 
duced IL-6 gene expression  and protein production as effectively as IL-I~. Both D-erythro-Cz- 
ceramide (a cell-permeable analogue of natural ceramide)  and D-threo-C2-ceramide were potent 
inducers of IL-6 production, while neither t  isomer of ceramide was effective. Compared with 
IL-l~-induced Ib6 production, cells treated with ceramide or exogenous sphingomyelinase in- 
duced 82 and 50% of maximal IL-l~-induced Ib6 levels by 6 h, respectively; by 24 h all three 
treatments induced similar levels of IL-6 production. Ceramide-induced IL-6 messenger KNA 
could be detected within 1 h of treatment and reached maximal levels by 24 h. These findings 
suggest that ceramide may play a role in the regulation of Ib6 gene expression. 
C 
eramide  has  emerged as  an  important  signal  trans- 
duction molecule that has been shown to play a role 
in such fundamental biological processes  as proliferation, 
differentiation, receptor function, oncogenesis, and immune 
and inflammatory responses (1-3).  Ceramide is generated by 
the hydrolysis of sphingomyelin (SM) via the activation of 
both neutral and acidic sphingomyelinase (SMase) (4). SM 
hydrolysis is stimulated by specific cytokines such as TNF-c~ 
(5-7), IFN-'y (8), and IL-lfl (9,  10). Noncytokine inducers 
of SM hydrolysis  include lo~,25-dihydroxyvitamin D3 (11) 
and brefeldin A  (12). 
We and others have shown that Iblfl stimulates SM hy- 
drolysis and the accumulation of ceramide in fibroblasts and 
EL4 lymphoma cells (9, 10). We also showed that ceramide 
modulated  the  effects  of IL-lfl  on  PGE2 production in 
human fibroblasts  via its ability to enhance the expression 
of the cyclooxygenase-1 gene (9). The ability of ceramide to 
modulate the effects of IL-lfl on PGE2 production led us to 
examine the effects of ceramide on II:lfl-mediated Ib6 produc- 
tion. II.-6 is a multifunctional cytokine produced by mono- 
cytes and macrophages, endothelial cells, vascular  smooth 
muscle cells, and fibroblasts  (13-16).  I1.-6 is known to acti- 
vate T cells, promote B cell growth and Ig synthesis, stimu- 
late synthesis of acute phase proteins by hepatocytes,  act as 
an endogenous pyrogen, induce megakaryocyte maturation, 
stimulate proliferation of keratinocytes,  and act as a growth 
factor for human myeloma and murine plastocytoma (15). 
IL-6 has been implicated in inflammation (13, 14, 17), viral 
infection (18), autoimmunity (15), development (19), and 
malignant cell growth (15). 
In an effort to establish the role of ceramide in IL-13-in- 
duced Ib6 production, we treated cells with stereoisomers 
of C2-ceramide or exogenous SMase and measured IL-6 pro- 
tein and messenger RNA (mKNA) levels. Here we show 
that the treatment of human fibroblasts  with ceramide or 
with exogenous SMase induces ID6 expression in a time- and 
dose-dependent manner. D-C2-ceramide, but not L-C2-cera- 
mide,  induced significant  production of IL-6 protein and 
mKNA at submicromolar concentrations, indicating a high 
degree of specificity for ceramide and the induction of II:6 
gene expression. Our findings suggest that ceramide may play 
a role in mediating the effects of Iblfl, and perhaps the effects 
of other agonists that induce SM hydrolysis, on IL-6 expres- 
sion in human fibroblasts. Given the many effects of IL-6 on 
a variety of different cell types, the identification of ceramide 
as an inducer of IL-6 production represents a potentially new 
and important role for SM signaling in the regulation of cell 
function. 
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Materials.  IL-6,  Ib1/8, Iblce, and TNF-o~ immunoassay kits were 
obtained from R&D Systems (Quantikine; Minneapolis, MN). Bac- 
terial SMase (Staphylococcus  aureus) was obtained from Sigma Chem- 
ical Co. (St. Louis, MO) and not purified further; using an in vitro 
assay system to test the specificity of hydrolysis, phosphatidylcho- 
line was hydrolyzed <5% compared with SM (100%). Ceramide 
stereoisomers were prepared and analyzed by nuclear magnetic res- 
onance as previously described (20). 
Cell Culture.  Human foreskin fibroblasts  were maintained in 
culture as previously described (9). Confluent fibroblast cultures 
were washed and incubated in fresh serum-free medium and treated 
with IL-1/8 (50 pgm/ml), ceramide, or bacterial SMase (1 mU/ml) 
along with appropriate vehicle controls. Ceramide stereoisomers 
were incubated with fatty acid-free BSA for 1 h as previously de- 
scribed (9) before their addition. The effect of ceramide on cell via- 
bility was assessed using trypan blue exclusion and DNA fragmen- 
tation; at all concentrations tested, ceramide had no apparent adverse 
affects. 
Immunoassay oflL-6 and ILL  IL6, IL-lol,  II.,1/8, and TNF-c~ 
levels in cell superuatants were measured by ELISA (R&D Systems) 
according to the manufacturer's directions. 
RNA Isolation and Northern Analysis of lL-6.  Total fibroblast 
cellular RNA was isolated from treated cells using the RNAzol 
method (Tel-Test, Inc., Friendswood, TX). RNA was fractionated 
on 1.2% agarose gels containing formaldehyde and blotted onto 
nitrocellulose membranes using capillary transfer (21). Blots were 
hybridized with either a 3zP-labeled IL-6 or GAPDH probe. Se- 
quences used as probes were generated by RT-PCR using the fol- 
lowing primers derived from human DNA sequences:  IL-6 sense 
5'-CCA GCT ATG AAC TCC TTC TCC AC-3'/antisense 5'-GGA 
CTG CAG GAA CTC CTT AAA GC-3'  (22);  GAPDH sense 
5'-CCA  CCC  ATG GCA  AAT  TCC  AT(3 GCA-3'/antisense 
5'-TCT AGA CGG CAG GTC AGG TCC ACC-3'(23). The PCR 
fragments were cloned into pCR II (Invitrogen, San Diego, CA). 
EcoRI-released inserts were subsequently used as substrates  for 
random primer labeling. Hybridizations were performed for 16-20 h 
at 42~  in sodium chloride sodium phosphate EDTA buffer con- 
taining 50% formamide. Hybridized membranes were autoradio- 
graphed on X-OMAT film (Eastman Kodak Co., Rochester, NY) 
at  - 80~ 
Results 
Ceramide Induces 11_,6 Expression.  In human foreskin fibro- 
blasts, IL-13 has been shown to induce SM hydrolysis and the 
accumulation of ceramide within 2 h  (9), and IL-13 is also 
known to be a potent inducer of IL-6 expression in these cells. 
Therefore, in an effort to establish whether ceramide is in- 
volved in the signal  transduction pathway by which IL-13 
induces Ib6 production, cells were treated with stereoisomers 
of C2-ceramide (1/xM final concentration), bacterial SMase 
(1 mU/ml), or IL-1/L After an overnight incubation, culture 
media were analyzed for IL-6 by ELISA. As shown in Fig. 
1,  both  D-erythro-  and  D-threo-C2-ceramide  induced  IL-6 
production  to  a  similar  extent  as  did  IL-13,  while  both 
L-erythro- and L-threo-C2-ceramide were ineffective inducers of 
IL-6 production.  This is not likely to be an artifact of un- 
equal  ceramide  uptake,  as  others  have  shown  that  these 
stereoisomers are taken up by cells with equal efficiency (20). 
Consistent with the hypothesis that SM hydrolysis may be 
involved in the IL-13 signaling pathway leading to IL-6 syn- 
thesis, treatment of cells with bacterial SMase also induced 
IL-6 production (Fig.  1). When cells were treated with ac- 
tinomycin D  to inhibit transcription, II.-6 production in re- 
sponse to IL-13,  C2-ceramide,  and bacterial SMase was re- 
duced >95%, indicating regulation of IL-6 induction at the 
transcriptional level (data not shown). Ceramide did not in- 
duce Iblot, IL-13, or TNF-c~ production in these cells, which 
could have resulted in an autocrine induction of IL-6 syn- 
thesis. Also, cells pretreated with Ibl receptor antagonist pro- 
tein (5 ng/well) inhibited IL-l-induced II.-6 production but 
had  no  affect  on  D-C2-ceramide-induced  Ib6  production 
(data not shown), suggesting that ceramide is able to induce 
Ib6 production in the absence of I1.-1 receptor stimulation. 
Dose-Response for Ceramide-induced 11.,6 Expression.  Fig. 
2  shows that,  at the lowest concentration tested in this ex- 
periment, only D-threo-C2-ceramide induced significant IL6 
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Figure  1.  The structures of the stereoisomers  of C2-ceramide (A), and 
the effect of I1,13, C2-ceramide  isomers, and bacterial SMase on IL-6 in- 
duction (B). Confluent dermal flbroblasts were treated with 1 ~  (final) 
D- or t-threo-C2-ceramide, D- or t-erythro-C2-ceramide,  50 pgm/m111-13, 
bacterial SMase (1 mU/ml), or vehicle  control in serum-ftee  medium. After 
24 h, culture media were collected and 11-6 protein levels were measured 
by ELISA. All data points depicted were derived from duplicate  11-6 assays 
from two identically treated wells •  SD. Five independent experiments 
gave similar quantitative data. 
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Figure  2.  Dose-response of C2-ceramide-induced IL-6 production. 
Confluent dermal fibroblast cultures in serum-free  medium were treated 
with the indicated final concentrations of D- or t-threo-Cz-ceramide  and 
D- or t-erythro-C2-ceramide. After 24 h,  the media were collected from 
identically treated duplicate wells and analyzed by IL-6  ELISA. The data 
presented are representative of four separate experiments. 
production.  D-erythro-C2-ceramide  effectively induced  IL-6 
production, but only at somewhat higher concentrations than 
the D-threo isomer. In contrast, neither of the r forms of cera- 
mide were effective inducers of IL-6 production (Fig. 2).  It 
is  noteworthy  that  the  submicromolar  concentration  of 
3-C2-ceramide  needed  to  induce  I~6  gene  expression  is 
among the lowest reported for such compounds  to elicit a 
specific biological response. 
Time Course  for IL.1fl,  Ceramide, and Bacterial SMase-induced 
IL.6 Expression.  Cells were treated with either IL-I~J, D-threo- 
C2-ceramide  (selected for further  study because it was  the 
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Figure 3.  Time course of 11,6 induction in response to IL1/~, D-threo- 
C2-ceramide, and bacterial SMase. Confluent dermal fibroblast cultures 
in serum-free  medium were treated with 50 pgm/m111,1B, 1 btM (final) 
D-threo-C2-ceramide, or bacterial SMase (1 mU/ml).  At the times indi- 
cated, the culture media were collected  from identically treated wells and 
analyzed by IL-6 ELISA. The data presented are from duplicate assays of 
two identically treated wells and are representative  of three separate ex- 
periments. 
most potent ceramide isomer tested), or bacterial SMase for 
the times indicated, and IL-6 production was measured (Fig. 
3).  IL-I~ rapidly induced  IL-6 production,  with  ~80%  of 
the maximal stimulation occurring by 2 h of incubation and 
100%  stimulation  by  6  h  of incubation.  Although  both 
D-threo-C2-ceramide and SMase induced measurable IL-6 pro- 
duction by 2 h  of incubation, both treatments were signifi- 
cantly less effective than IL-lfl, suggesting the activation of 
multiple pathways by IL-1/3 leading to IL-6 production.  As 
the time of incubation increased, both D-threo-C2-ceramide- 
and SMase-induced  IL-6 production continued  to increase; 
by the end of a 24-h treatment, cells treated with either IL-I~, 
D-threo-C2-ceramide,  or SMase produced essentially equiva- 
lent  amounts  of IL-6 (Fig.  3). 
Steady  State  Levels of IL,6  mRNA  Induced by D-threo-C2- 
Ceramidr  Total RNA from cells treated with increasing con- 
centrations  of  D-threo-Cz-ceramide  was  size  fractionated, 
blotted, and hybridized with an IL-6 cDNA probe. The same 
Northern blot was also hybridized with a GAPDH cDNA 
probe to monitor changes in a constitutively expressed mRNA 
after  treatment  with  C2-ceramide.  Fig.  4  shows  the  data 
from a representative dose-response experiment in which cells 
were treated with D-threo-C2-ceramide at the concentrations 
indicated for 24 h. There was a dear, dose-dependent increase 
in IL-6 mRNA in response to ceramide, and significant IL-6 
induction  was  observed at  the lowest  concentration  tested 
in these experiments,  5  x  10-9 m.  The specificity of IL-6 
mP,  NA induction can be readily appreciated from the lack 
of significant changes in the steady state levels of GAPDH 
mRNA  (Fig.  4). 
To establish the time course of IL-6 mRNA  induction in 
response  to  ceramide,  cells  were  treated  with  D-threo-C2- 
ceramide for 0,  1, 3,  6,  and 24 h,  and total RNA was ana- 
lyzed by Northern hybridization as above. Ceramide rapidly 
induced IL-6 mRNA,  which was detectable by 1 h  and dra- 
matically increased by 3 h (Fig. 5). We consistently observed 
a  slight  decrease in IL-6  mRNA  levels after 6  h  of incuba- 
tion; however, no corresponding decrease in IL-6 protein levels 
was seen at 6 h. IL-6 mRNA levels continued to increase over 
the remaining  course of the incubation  with  ceramide. 
Figure 4.  Dose-response for 
the steady state induction of Ib6 
mRNA by D-threo-C2-ceramide. 
Confluent dermal  fibroblasts  were 
treated with the indicated  concen- 
trations  of D-threo-Cz-ceramide, 
50 pgm/ml IL-13, or vehicle  con- 
trol in serum-free  medium. Total 
RNA was isolated  after a 24-h in- 
cubation,  and  20  /~g  of  each 
sample was analyzed by gel elec- 
trophoresis  followed  by Northern 
blot. The blotted membrane was 
hybridized  with a 32P-labeled  I1,6 
probe, stripped, and rehybridized with a GAPDH probe. Lane I, IL-13; 
lane 2, no additions; lane 3, o-threo-C2-ceramide  (5  x  10 -9 M); lane 4, 
D-threo-C2-ceramide  (1  x  10 -s M); lane 5, D-threo-C2-ceramide  (1  x  10 -7 
M); and lane 6, D-threo-C2-ceramide  (1  x  10 -6 M). 
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induction by D-threo-C2-ceramide. Con- 
fluent dermal fibroblasts  were  treated  with 
1/LM D-threo-C2-ceramide  in serum-free 
medium for the indicated times, after 
which total RNA was isolated. 10/~g of 
each sample  was analyzed  by gel electro- 
phoresis followed  by Northern blot. The 
blotted membrane was hybridized with 
a 32p-hbeled  Ib6 probe, stripped, and re- 
hybridized with a GAPDH  probe. Incu- 
bation times with  D-threo-C2-ceramide 
(1/xM): lane I, "zero"; lane 2, 1 h; lane 
3, 3 h; lane 4, 6 h; and lane 5, 24 h. 
Discussion 
IL-6 is a multifunctional cytokine produced by many differ- 
ent cell types, including  fibroblasts.  The expression of IL-6 
is regulated by a variety of agonists, including IL-1, TNF-ot, 
platelet-derived growth  factor,  interferons,  and glucocorti- 
coids (24, 25). Studies of Ib6 induction in response to TNF-ot 
and IL-1/3 in human  fibroblasts have revealed that both the 
protein kinase C  (26) and cAMP-dependent  protein  kinase 
A pathways (27) are involved. However, it is also recognized 
that  these signaling  pathways may not completely account 
for IL-6 induction by IL-13 and TNF-ot (28). Because these 
cytokines also stimulate SM hydrolysis, resulting in increased 
intracellular ceramide (8, 9), we examined the possibility that 
ceramide may be involved in the signaling pathway leading 
to  the induction  of IL-6 production. 
IL-6 gene expression in human  fibroblasts was inducible 
with  the addition  of nanomolar  concentrations  of D-threo- 
Cz-ceramide.  Maximal induction of IL-6 in response to cer- 
amide required concentrations well below the levels known 
to result in toxicity or apoptosis in cultured cells  (29,  30). 
Although the kinetics of induction of IL-6 by human fibro- 
blasts was somewhat  slower in ceramide-treated  cells  than 
in IL-13-treated cells,  equivalent IL-6 levels accumulated by 
24 h. The difference in time courses between IL-13 and cera- 
mide could be due to the possibility that  the activation  of 
the SM pathway accounts for only a portion of the signaling 
pathway involved in the IL-1/3-mediated induction  of Ib6. 
This is likely, because IL-13-induced IL-6 production in cul- 
tured  human  fibroblasts  has  been  shown  to  involve both 
the  cAMP/protein  kinase  A  pathway  (27)  and  the  diacyl- 
glycerol/protein kinase C pathway (26). Because of the acti- 
vation of multiple  stimulatory pathways in addition  to the 
SM pathway,  the more rapid  induction  of IL-6 production 
in response to IL-3, compared with  the addition  of exoge- 
nous ceramide by itself, is not an unexpected result.  Ibl causes 
an increase in cAMP levels  more quickly than  it  causes  an 
increase in ceramide levels. Another possible reason for the 
time course difference between IL-1/3 and C2-ceramide-medi- 
ated induction oflb6 could be a difference in "effective" con- 
centration  of ceramide  at  a specific  site of action.  Because 
the IL-I~ receptor is most likely linked to the activation of 
a "specific" SMase, the receptor-coupled action of IL-13 could 
result in a higher concentration of ceramide at a specific site 
of action when  compared with  intracellular  levels of cera- 
mide entering  the cell by nonspecific diffusion through  the 
plasma membrane. Although SMase-mediated IL-6 induction 
is somewhat  slower than  that  of C2-ceramide,  the level  of 
Ib6 after 24 h  is similar  to that  induced by Ib13  and C2- 
ceramide.  This might be due to the rate at which ceramide 
is produced in response to exogenous SMase treatment.  It 
is also possible that the time course difference between SMase 
and C2-ceramide relates to the difference in length of amide- 
linked acyl chains between C2-ceramide and the natural cer- 
amide (mostly C16-ceramide),  or it may be due to the fact 
that,  unlike natural C16-cerarnide, C2-ceramide  is not metab- 
olized and  therefore provides a more stable signal. 
Our results indicate that the D isomers of ceramide are far 
better inducers of II.-6 than are the corresponding t  isomers. 
In contrast,  the t  isomers of ceramide have been shown to 
be more effective than the D isomers for inhibiting the prolifer- 
ation of HL-60 cells (20). These unique specificities  for cera- 
mide stereoisomers in different cell types remain an enigmatic 
question and suggest potential differences in the cellular targets 
for ceramide action.  With respect to targets of ceramide ac- 
tion, there have been at least two ceramide-activated enzymes 
described: a proline-directed serine/threonine protein kinase 
(5) and a ceramide-activated  protein phosphatase (CAPP) (31). 
At the present time, it is not known whether either of those 
two enzymes is involved in the induction of ILo6 or whether 
the activation of another as yet unidentified signal transduc- 
tion  pathway is involved. 
Our finding that the D isomers of ceramide are more effec- 
tive than  the t  isomers in the induction  of IL-6 expression 
implicates the stereochemistry at carbon 3 as critical for their 
action.  The number 3 carbon was also concluded to be im- 
portant using structural analogues of ceramide in regulating 
cellular proliferation (29). The specificity of ceramide for IL-6 
gene induction would appear to be different from that of the 
activation of CAPP, in which all four ceramide stereoisomers 
were equally effective activators of the purified enzyme (31). 
These observations would suggest that the signaling pathway 
involved in the ceramide-mediated induction of IL-6 gene ex- 
pression may be distinct  from that of CAPP activation and 
the related  down-regulation  of c-myc  (31). 
The induction of ILo6 by C2-ceramide appears  to be regu- 
lated at the transcriptional  level,  as evidenced by the ability 
of actinomycin  D  to  completely inhibit  ceramide-induced 
IL-6 production.  Further,  Northern  blot  analysis  revealed 
that  C2-ceramide induces IL-6 mRNA in a dose-dependent 
manner with a time course paralleling  the accumulation  of 
IL-6 protein. Studies using two different cell types have shown 
that ceramide activates NF-xB (7, 32), a transcription  factor 
known to be involved in IL-l-induced IL-6 gene expression 
(33, 34). Therefore, there is a possibility that ceramide may 
induce IL-6 gene expression through  the activation  of NF- 
xB, and experiments designed to test the hypothesis are cur- 
rently underway. 
IL-6 gene regulation has been extensively studied in a wide 
variety of experimental  systems, and the ability of IL-l~8 to 
induce IL-6 production is well established. Here we have im- 
plicated signaling  via the SM pathway in the regulation  of 
602  Ceramide  Induces Ib6 Gene Expression IL6 gene expression. The induction of IL-6 by ceramide in 
human fibroblasts demonstrates the ability of a specific SM 
metabolite to induce the expression of a distinct gene and 
will provide an excdbnt modal system for studying the mech- 
anisms involved in the regulation of gene expression by SM 
metabolites. 
We are very grateful to Carolyn  Chambers for her expert technical assistance. 
This work was supported by research funds from the Department of Veterans Affairs and The Arthritis 
Foundation, and by grants AR39166 and AR26034 from the National  Institute  of Arthritis  and Mus- 
culoskeletal and Skin Diseases, National Institutes of Health. R. Raghow is a career scientist of the Depart- 
ment of Veterans Affairs. 
Address correspondence to Dr. Leslie  R. Ballou, Department of Veterans Affairs Medical Center, Research 
Service (151), 1030 Jefferson Avenue, Memphis, TN 38104. 
Received for publication  17January  I995 and in revised  firm  8 March  I995. 
References 
1.  Ballou, L.R. 1992. Sphingolipids and cell function. Immunol. 
Today. 13:339-341. 
2.  Hannun, Y.A. 1994. The sphingomyelin cycle and the second 
messenger function ofceramide.J. Biol. Chem. 269:3125-3128. 
3.  Kolesnick, R.,  and D.W. Golde.  1994. The sphingomyelin 
pathway in tumor necrosis factor and interleukin-1 signaling. 
Cell. 77:325-328. 
4.  Wiegmann, K., S. Schutze, T. Machleidt, D. Witte, and M. 
Kronke.  1994. Functional  dichotomy  of neutral  and acidic 
sphingomyelinases in  tumor necrosis factor signaling.  Cell. 
78:1005-1015. 
5.  Dressier, K.A., S. Mathias, and R.N. Kolesnick. 1992. TNFc~ 
activates the sphingomyelin signal transduction pathway in a 
cell-free system. Science (Wash. DC).  255:1715-1717. 
6.  Dbaibo, G.S., L.M. Obeid,  and Y.A. Hannun. 1993. Tumor 
necrosis factor-alpha  (TNF-cr  signal transduction through cer- 
amide. Dissociation of growth inhibitory effects  of  TNF-ct from 
activation of  nuclear factor-kB.J. Biol. Chem. 268:17762-17766. 
7.  Schutze, S., K. Potthoff, T. Machleidt, D. Berkovic, K. Wieg- 
mann,  and  M.  Kronke.  1992. TNF  activates NF-KB by 
phosphatidylcholine-specific  phospholipase C-induced "acidic" 
sphingomyelin breakdown.  Cell. 71:765-776. 
8.  Kim,  M.Y., C.  Linardic, L.  Obeid,  and Y. Hannun.  1991. 
Identification of  sphingomyelin turnover as an effector mecha- 
nism for the action of tumor necrosis factor c~ and 3,-interferon. 
Specific role in cell differentiation.J. Biol. Chem. 266:484-489. 
9.  Ballou, L.R., C.P. Chao, M.A. Holness, S.C. Barker, and R. 
Raghow. 1992. Interleukin-l-mediated  PGE2 production and 
sphingomyelin metabolism. Evidence for the regulation of cy- 
clooxygenase gene expression by sphingosine and ceramide.J. 
Biol. Chem. 267:20044-20050. 
10.  Mathias, S., A. Younes, C.C. Kan, I. Orlow, C. Joseph, and 
R.N. Kolesnick. 1993. Activation of the sphingomyelin sig- 
naling pathway in intact  EL4 cells and in a cell-free system 
by IL-13. Science (Wash. DC). 259:519-522. 
11.  Okazaki,  T.,  R.M.  Bell, and  Y.A. Hannun.  1989. Sphin- 
gomyelin turnover induced by vitamin D3 in HL-60 cells. Role 
in cell differentiation. J. Biol. Chem. 264:19076-19080. 
12.  Linardic, C.M., S. Jayadev, and Y.A. Hannun. 1992. Brefeldin 
A promotes hydrolysis of sphingomyelin.J.  Biol. Chem. 267: 
14909-14911. 
13.  Hirano, T. 1992. The biology ofinterleukin-6. Chem. Immunol. 
51:153-180. 
14.  Hirano, T. 1992. Interleukin-6 and its relation to inflamma- 
tion and disease. Clin. Immunol. Immunopathol. 62:60-65. 
15.  Kishimoto, T., S. Akira, and T. Taga. 1992. Interleukin-6 and 
its  receptor:  a paradigm for cytokines. Science (Wash. DC). 
258:593-597. 
16.  Kishimoto, T. 1992. Interleukin-6 and its receptor in autoim- 
munity, f  Autoimmun.  5:123-132. 
17.  Hirano, T., S. Akira, T. Taga, and T. Kishimoto.  1990. Bio- 
logical and clinical aspects of interleukin-6. Immunol. Today. 
11:443-449. 
18.  Akira, S., and T. Kishimoto. 1992. IL6 and NF-IL6 in acute- 
phase response and viral infection. Immunol. Rev. 127:25-50. 
19.  Lee,  F.D. 1992. The role ofinterleukin-6 in development. Dev. 
Biol. 151:331-338. 
20.  Bielawska,  A., H.M. Crane, D. Liotta, L.M. Obeid, and Y.A. 
Hannun. 1993. Selectivity of ceramide-mediated  biology. Lack 
of activity  of erythro-dihydroceramide, j.  Biol. Chem. 268: 
26226-26232. 
21.  Sambrook, J., E.F. Fritsch, and T. Maniatis. 1989. Molecular 
Cloning: A Laboratory Manual. Second edition. Cold Spring 
Harbor Laboratory, Cold Spring Harbor,  NY. 
22.  Hirano, T., T. Taga, K. Yamasaki, T. Matsuda, K. Yasudawa, 
Y. Harata, H. Yawata, O. Tanabe, S. Akira, and T. Kishimoto. 
1989. Molecular cloning of the cDNAs for interleukin 6/B 
cell stimulatory factor 2 and its receptor. Ann. NY Acad. Sci. 
557:231-238. 
23.  Ercolani, L., B. Florence, M. Denaro, and M. Alexander. 1988. 
Isolation and complete sequence of a functional human glyc- 
eraldehyde-3-phosphate dehydrogenase. J.  Biol. Chem. 263: 
15335-15341. 
24.  Sehgal, P.B. 1992. Regulation  of IL-6 gene expression. Res. 
Immunol. 143:724-734. 
25.  Ray,  A., S. Laforge, and P.B. Sehgal. 1990. On the mechanism 
for efftcient repression of the IL-6  promoter by glucocorticoids: 
Enhanced TATA box and RNA start site (INR motif). Mol. 
Cell. Biol. 10:5736-5746. 
26.  Sehgal, P.B., Z. Walther, and I. Tamm. 1987. Rapid enhance- 
ment of beta 2-interferon/B-cell differentiation factor BSF-2 
gene expression in human fibroblasts by diacylglycerols and 
the calcium ionophore  A23187. Proa Natl. Acad. Sci. USA. 
84:3663-3667. 
603  Laulederkind  et al.  Brief  Definitive Report 27.  Zhang, Y., J.-X. Lin, and J. Vilcek. 1988. Synthesis of inter- 
leukin 6 (interferon-beta  2/B cell stimulatory factor 2) in human 
fibroblasts is triggered by an increase in intracellular cyclic AMP. 
J. Biol. Chem.  263:6177-6182. 
28.  Akira,  S.,  T.  Hirano, T.  Taga, and T.  Kishimoto.  1990. Bi- 
ology of multifunctional cytokines: II.-6 and related molecules 
(IL-1 and TNF).  FASEB J. 4:2860-2867. 
29.  Bielawska, A., C.M. Linardic, and Y.A. Hannun. 1992. Modu- 
lation of cell growth and differentiation by ceramide. FEBS 
Lett. 307:211-214. 
30.  Obeid, L.M., C.M. Linardic, L.A. Karolak, and Y.A. Hannun. 
1993.  Programmed cell  death  induced  by ceramide. Science 
(Wash. DC).  259:1769-1771. 
31.  Wolff, K.A.,  R.T.  Dobrowsky, A.  Bielawska,  L.M.  Obeid, 
and Y.A. Hannun.  1994.  Role of ceramide-activated protein 
phosphatase in ceramide-mediated signal transduction.J. Biol. 
Chem. 269:19605-19609. 
32.  Yang, Z., M. Costanzo, D.W. Golde, and R.N. Kolesnick. 1993. 
Tumor necrosis factor activation of the sphingomyelin pathway 
signals  nuclear factor gB translocation in intact HD60 cells. 
J. Biol. Chem.  268:20520-20523. 
33.  Shimizu,  H.,  K.  Mitomo,  T.  Watanabe,  S.  Okamoto,  and 
K.-I. Yamamoto. 1990.  Involvement of an NF-gB-like tran- 
scription factor in the activation of the 1I.-6 gene by inflamma- 
tory cytokines. Mol. Cell. Biol. 10:561-568. 
34.  Zhang, Y., J.-X. Lin, and J. Vilcek.  1990. 11.-6 induction by 
TNF and 1I.-1 in human fibroblasts involves activation of a nu- 
clear  factor binding  to  a  KB-like sequence.  Mol. Cell. Biol. 
10:3818-3823. 
604  Ceramide Induces II.-6 Gene Expression 